{"commentary":{"count":42,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":21,"podcast":11,"youtube":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05243797\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MajesTEC-4","nct_id":"NCT05243797","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=majestec-4-nct05243797. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"MajesTEC-4","arms":[{"description":"Teclistamab will be administered via a subcutaneous injection (SC)","label":"Arm A: Teclistamab-Lenalidomide (Tec-Len)","type":"EXPERIMENTAL"},{"description":"Lenalidomide orally.","label":"Arm B Lenalidomide Alone (Len)","type":"ACTIVE_COMPARATOR"},{"description":"Teclistamab will be administered via a subcutaneous injection (SC)","label":"Arm C Teclistamab-Alone (Tec)","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica"],"completion_date":{"date":"2032-04","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":1594,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Teclistamab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"European Myeloma Network B.V.","official_title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"from randomization to the date of disease progression or death (approximately up to 8 years)"},{"measure":"Minimal Residual Disease (MRD)-negative Complete Response (CR)","timeFrame":"at month 12"}],"references":[],"start_date":{"date":"2022-09-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","url":"https://clinicaltrials.gov/study/NCT05243797"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/majestec-4-nct05243797"}